Video

Dr. Rizvi on Treatment Considerations in Stage III/IV Hodgkin Lymphoma

Author(s):

Syed Rizvi, MD, an assistant professor in the Department of Internal Medicine at UT Southwestern Medical Center, discusses treatment considerations in stage III/IV Hodgkin lymphoma.

Syed Rizvi, MD, an assistant professor in the Department of Internal Medicine at UT Southwestern Medical Center, discusses treatment considerations in stage III/IV Hodgkin lymphoma.

The age of the patient, their smoking history, the condition of their lungs, and a history of lung disease, neuropathy or predisposition therein are all important factors to consider in treatment selection, says Rizvi.

Doxorubicin, vincristine, dacarbazine (AVD), and bleomycin was the standard chemotherapy for frontline treatment in North America, says Rizvi. In March 2018, the FDA approved brentuximab vedotin (Adcetris) plus AVD (A+AVD) for up-front use, allowing for treatment to be tailored according to a patient’s comorbidities. As such, nonsmokers or those who have no history of cytopenia are typically treated with A+AVD, concludes Rizvi.

Related Videos
Jonathan Spicer, MD, PhD, FRCS
Daniel DeAngelo, MD, PhD
Marc J. Braunstein, MD, PhD, associate professor, Department of Medicine, co-director, Hematology-Oncology System, New York University (NYU) Grossman Long Island School of Medicine
Douglas W. Sborov, MD, MS, associate professor, Department of Internal Medicine—Division of Hematology and Hematologic Malignancies; director, Hematology Disease Center and Plasma Cell Dyscrasias Program, the University of Utah Huntsman Cancer Institute
Bradley C. Carthon, MD, PhD
David C. Fisher, MD
Alan Tan, MD
Binod Dhakal, MD
Sheldon M. Feldman, MD
Yair Lotan, MD, UT Southwestern Medical Center